Abstract
Several animal models, as well as a number of cell culture experiments, indicate a prophylactic effect of bisphosphonates in respect of subsequent bone metastasis. Moreover, in preliminary clinical trials involving patients with advanced breast cancer and local or remote metastases, biophosphonates produced a reduction in new skeletal metastases. This overview summarizes and discusses the results of the latest investigations. It opens with a section on the pathophysiology of bone metastasis, which is followed by a report on animal models and first studies of bisphosphonate treatment as a new approach in systemic adjuvant therapy. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aparicio A, Gardner A, Tu Y, Savage A, Berenson J and Lichtenstein A (1998) In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12: 220–229
Averbuch SD (1993) New bisphosphonates in the treatment of bone metastases. Cancer 72: 3443–3452
Benford HL, Frith JC, Auriola S, Mönkkönen J and Rogers MJ (1999) Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 56: 131–140
Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J and Knight RD (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced myeloma. N Engl J Med 334: 488–493
Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J and Knight RD (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 16: 593–602
Bloomfield DJ (1998) Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 16: 121812–121825
Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD and Clezardin P (1997) Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrix. Cancer Res 57: 3890–3894
Bundred NJ, Walker RA, Ratcliffe WA, Warwick J, Morrison JM and Ratcliffe JG (1992) Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur J Cancer 28: 690–692
Busch M, Rave-Fränk M, Hille A and Dühmke E (1998) Influence of clodronate on breast cancer cells in vitro. Eur J Med Res 3: 427–431
Coleman RE and Rubens RD (1985) Bone metastases and breast cancer. Cancer Treat Rev 12: 251–270
Coleman RE and Rubens RD (1987) The clinical course of bone metastases in breast cancer. Br J Cancer 55: 61–66
Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R and Campos D (1996) Bonneterre J, Francini G and Ford JM. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 14: 2552–2559
Coxon FP, Russell RGG and Rogers MJ (1995) Pathways of bisphosphonate-induced apoptosis in murine macrophage-like cells. Bone 17: 600
Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P and Bremond A (1997) Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 15: 955–962
Diel IJ, Costa SD, Kaufmann M and Bastert G (1994) Detection and characterization of tumor cells in bone marrow of patients with primary breast cancer. Metastatic Bone Disease. Fundamental and Clinical Aspects Diel IJ, Kaufmann M, Bastert G (eds), pp 31–45, Springer: Berlin
Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S and Bastert G (1996) Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison to nodal status. J Natl Cancer Inst 88: 1652–1664
Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M and Bastert G (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339: 357–363
Diel IJ, Solomayer EF, Seibel M, Pfeilschifter J, Maisenbacher H, Gollan CH, Conradi R, Naser W, Hoyle N and Bastert G (1999) Serum bone sialoprotein and crosslaps are both highly predictive for bone metastases in breast cancer. Proc Am Ass Cancer Res 40: 2168
Elomaa I, Blomqvist C, Gröhn P, Porkka L, Kairento AL, Selander K, Lambert-Allardt C and Holmström T (1983) Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet I: 146–149
Elomaa I, Blomqvist C, Porkka L, Lambert-Allardt C and Borgström GH (1987) Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone 8: 53–56
Fleisch H (1997) Bisphosphonates in Bone Disease. From the Laboratory to the Patient Parthenon: New York
Ford JM, van Oosterom, Brincker H, Kandra A and Body JJ (1998) Oral pamidronate: negative results from 3 double-blind, placebo-controlled trials in hypercalcemia, myeloma, and the prevention of bone metastases. Bone 22: 3
Frith JC, Mönkkönen J, Blackburn GM, Russell RG and Rogers MJ (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5-(beta, gamma-dichlormethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12: 1358–1367
Fromigue D, Siwek B and Body JJ (1999) Bisphosphonates inhibit breast cancer cell proliferation. Calcif Tissue Int 64
Galasko CSB (1986) Skeletal Metastases. Butterworth: London
Guaitani A, Polentarutti S, Filipeschi S, Marmonti L, Corti F, Italia C, Coccioli G, Donelli MG, Mantovani A and Garattini S (1984) Effects of disodium etidronate in murine tumor models. Eur J Cancer Clin Oncol 20: 685–693
Guise TA, Yin JJ, Taylor SD, Yoneda T, Dallas M, Boyce BF, Kumagai Y and Mundy GR (1996) Evidence for a causal role of parathyroid hormone related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98: 1544–1549
Hall DG and Stoica G (1994) Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. J Bone Miner Res 9: 221–230
Henderson MA, Danks JA, Slavin J, Moseley JM, Harris T and Martin TJ (1999) Production of PTHrP by primary breast cancers predicts improved patient survival and decreased bone metastases. J Bone Miner Res 14
Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD, Heffernan M and Reitsma DJ (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335: 1785–1791
Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight R, Heffernan M, Mellars K and Reitsma D (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 16: 2038–2044
Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR and Boyce BF (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10: 1478–1487
Jung A, Bomand J, Mermillod B, Edouard C and Meunier PJ (1984) Inhibition by diphosphonate of bone resorption induced by the Walker tumor of the rat. Cancer Res 44: 3007–3011
Kanis JA (1995) Bone and cancer: pathophysiology and treatment of metastases. Bone 17: 101S–105S
Kanis JA, Powles TJ, Paterson AHG, McCloskey EV and Ashley S (1996) Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19: 663–667
Kostenuik PJ, Orr FW, Suyama K and Singh G (1993) Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate treated rats. Cancer Res 53: 5472–5477
Krempien B, Wingen F, Eichmann T, Müller M and Schmähl D (1988) Protective effect of a prophylactic treatment with the bisphosphonate 3-amino-1-hydroxypropane-1,1 bisphonic acid on the development of tumor osteopathies in rat: experimental studies with the Walker Carcinosarcoma 256. Oncology 45: 41–46
Krempien B (1994) Morphological findings in bone metastasis, tumorosteopathy and antiosteolytic therapy. Metastatic Bone Disease. Fundamental and Clinical Aspects Diel IJ, Kaufmann M, Bastert G (eds), pp 59–85, Springer: Berlin
Krempien B (1996) Experimental findings on the osteoprotective potential of bisphosphonates against bone metastases and tumor-induced osteopathy: a pleading for an early and preventive administration. Bone Metastasis – Mechanisms and Pathophysiology Orr FW, Singh G (eds), pp 221–244, Landes: Georgetown, TX
Krempien B and Manegold C (1993) Prophylactic treatment of skeletal metastases, tumor-induced osteolysis, and hypercalcemia in rats with the bisphosphonate CL2MBP. Cancer 72: 91–98
Luckman SP, Hughes DE, Coxon FP, Russell RGG and Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins. J Bone Miner Res 13: 581–589
McCloskey EV, MacLennan ICM, Drayson M, Chapman C, Dunn J and Kanis JA (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 100: 317–325
Mönkkönen J, Taskinen M, Auriola SOK and Urtti A (1994) Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro. J Drug Target 2: 299–308
Müller M, Green JR and Fabbro D (1996) The bisphosphonate pamidronate inhibits the growth of a murine myeloma cell line in syngeneic mice. Blood 88/10: 2333
Mundy GR (1991) Mechanism of osteolytic bone destruction. Bone 12: 1–6
Mundy GR (1995) Bone Remodeling and Its Disorder Dunitz: London
Nemoto R, Uchida K, Tsutsumi M, Koiso K, Sigenori S and Tetsuro S (1987) A model of localized osteolysis induced by the MBT-2 tumor in mice and its responsiveness to etidronate disodium. J Cancer Res Clin Oncol 113: 539–543
Paterson AHG, Powles TJ, Kanis JA, McCloskey EV, Hanson J and Ashley S (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11: 59–65
Powles TJ, Paterson AHG, Nevantaus A, Legault S, Pajunen M, Tidy VA, Rosenqvist K, Smith IE, Ottestad L, Ashley S, Walsh G, McCloskey E and Kanis JA (1998) Adjuvant Clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer. Proc Am Soc Clin Oncol 17
Reitsma PH, Teitelbaum SL, Bijvoet OLM and Kahn AJ (1982) Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (CI2MDP) on rat macrophage-mediated bone resorption in vitro. J Clin Invest 70: 927–933
Rodan GA and Fleisch H (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97: 2692–2696
Rogers MJ, Chilton KM, Coxon FP, Lawry J, Smith MO, Suri S and Russel RGG (1996) Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res 11: 1482–1491
Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Mönkkönen J, Auriola S, Chilton KM and Russell RGG (1999) Molecular mechanism of action of bisphosphonates. Bone 24: 73S–79S
Rubens RD (1992) The nature of metastatic bone disease. Bone Metastases. Diagnosis and Treatment Rubens RD, Fogelman I (eds), pp 1–10, Springer: London
Saarto T, Blomqvist C, Välimäki M, Mäkelä P, Sarna S and Elomaa I (1997 a) Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 15: 1341–1347
Saarto T, Blomqvist C, Välimäki M, Mäkelä P, Sarna S and Elomaa I (1997 b) Clodronate improves bone mineral density in postmenopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 75: 602–605
Saarto T, Blomqvist C, Virkkunen P and Elomaa I (1999) No reduction of bone metastases with adjuvant clodronate treatment in node-positive breast cancer patients. Proc Am Soc Clin Oncol 18(Abstract 489)
Sasaki A, Boyce BF, Wright KR, Chapman M, Boyce R, Mundy GR and Yoneda T (1995) Bisphosphonate risedronate reduces metastatic human breast cancer burden in nude mice. Cancer Res 55: 3551–3557
Selander KS, Mönkkönen J, Karhukorpi EK, Harkonen P, Hannuniemi R and Vaananen HK (1996) Characteristics of clondronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 50: 1127–1138
Shipman CM, Rogers MJ, Apperley JF, Russell RGG and Croucher P1 (1997) Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumor activity. Br J Haematol 98: 665–672
Shipman CM, Croucher PI, Russell RGR, Helfrich MA and Rogers MJ (1998) The bisphosphonate incadronate (YM 175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58: 5294–5297
Stearns ME and Wang M (1996) Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis 16: 116–131
Theriault RL and Hortobagyi GN (1992) Bone metastasis in breast cancer. Anticancer Drugs 3: 455–462
Van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Löwik C and Papapoulos S (1996) Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98: 698–705
Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, Cleton FJ, Beex LVAM, Blijham G, Hermans J, Neijt JP, Papapoulos SE, Sleeboom HP, Vermey P and Zwinderman AH (1993) Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11: 491–498
Van Holten-Verzantvoort ATM, Hermans J, Beex LVAM, Blijham G, Cleton FJ, van Eck-Smit BCF, Sleeboom HG and Papapoulos SE (1996) Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients?. Eur J Cancer 32: 450–454
Weiss L and Gilbert AH (1981) Bone Metastasis. Hall: Boston
Wingen F, Eichmann T, Manegold C and Krempien B (1986) Effects of new bisphonic acids on tumor-induced bone destruction in the rat. J Cancer Res Clin Oncol 111: 35–41
Wingen F, Pool BL, Klein P, Klenner T and Schmähl D (1988) Anticancer activity of bisphosphonic acids in methylnitrosurea-induced mammary carcinoma of the rat – benefit of combining bisphosphonates with cystatic agents. Invest New Drugs 6: 155–167
Yoneda T, Sasaki A, Dunstan C, Wiliams PJ, Bauss F, DeClerck YA and Mundy GR (1997) Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with bisphosphonate and tissue inhibitor of matrix metalloproteinase-2. J Clin Invest 99: 2509–2517
Author information
Authors and Affiliations
Consortia
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Diel, I., Mundy, G. & Cancer Study Group (IBCG). Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. Br J Cancer 82, 1381–1386 (2000). https://doi.org/10.1054/bjoc.1999.1077
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.1077
Keywords
This article is cited by
-
Roles of osteoclasts and bone-derived IGFs in the survival and growth of human breast cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice
Clinical & Experimental Metastasis (2008)
-
Elevated level of cell-free plasma DNA is associated with breast cancer
Archives of Gynecology and Obstetrics (2007)
-
Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma
Medical Oncology (2007)